GILD is a HEAVY BUY

Gilead has been in a heavy consolidation pattern around the $100 price level for the last 8 months and is about to breakout to the upside. The biotech sector as a whole is ready to start consolidating and some big M&A is about to happen. There has been lots of talk this weekend reinforcing arguments that GILD is getting ready to spend some of its $14 billion USD in cash it has. Some analysts believe that an acquisition by GILD of VRTX could be the catalyst to launch the stock above its 52 week high of $116.83. In other M&A news TEVA is trying to buyout MYL for $40 billion and Mylan (MYL) is trying to buy PRGO (Perrigo) for $34 billion. MYL has also stated that upon acquiring PRGO it would be interested in buying TEVA. What this means is a 3 way buyout battle has ensued and the crown jewel GILD has just announced a pact to let MYL distribute Sovaldi in Egypt. VRTX has a big day ahead of it on Tuesday the FDA will vote on whether to recommend approval for their flagship cystic fibrosis drug Orkambi. If approved expect GILD to move in swiftly and announce a buyout before the stock goes to much higher.

GILD a BUY and I believe shares are just about to do a short squeeze and breakout above 52 week high within 30 days.
1 month price target of 117 - 122
3 month price target of 130 - 135

Articles to cite information from and encourage viewers to read:

www.wsj.com/articles...-big-test-1431163983
www.benzinga.co...ablets-in-india?utm_campai...
www.cnbc.com/id/102662818
blogs.wsj.com/moneyb...ell-do-what-we-want/
seekingalpha.com/new...ers-analyst-suggests